CI	41	F	F٦	Г	1	0	_	•
JI	11		Г				Г.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.	APPLICATION NO.	
VICAL.035A	08/210,902	
APPLICANT		
Nabel, E., et al.		_
FILING DATE	GROUP	
March 21 1004	1004	

	AFFEICAN		
INFORMATION DISCLOSURE STATEMENT	Nabel, E., et al.		
BY APPLICANT	FILING DATE	GROUP	<u>-</u>
(USE SEVERAL SHEETS IF NECESSARY)	March 21, 1994	1804	

			U.S. PATENT DOCUMENTS			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	*					
		T .			,	

			FOREIGN PATENT DOCUMENTS			-	
EXAMINER	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI	_ATION
INITIAL				<u> </u>		YES	NO
					·		
						-	

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
oc	Α	Casscells, W., et al. (1992) Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc. Natl. Acad. Sci. 89:7159-7163.
δυ.	В	Guzman, R., et al. (1993) Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation 88(6):2838-2848.
de	С	Mazur, W., et al. (1994) Coronary restenosis and gene therapy. Coronary Restenosis and Gene Therapy 21(1):104-111.
di	D	Ohno, T., et al. (1994) Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265:781-784.
de	Ε	Takeshita, S., et al. (1994) Increased gene expression after liposome-mediated arterial gene transfer associated with intimal smooth muscle cell proliferation. J. Clin. Invest. 93:652-661.
di	F	Venkatesh, L., et al. (1990) Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 tat by a conditionally cytotoxic adenovirus vector. Proc. Natl. Acad. Sci. 87:8746-8750.

EXAMINER	Deborel Cronce	DATE CONSIDERED 3/28/96
	THE ATTATION OF THE PARTY OF TH	ATTATION TO THE CONFORMANCE LITTLE MEET CON DEAL LITTLE THOUGH ATTATION TO NOT THE

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

ANK: 5979
092195